Evolution of the Average Target: Vaxart, Inc.

Evolution of the Target Price: Vaxart, Inc.

Changes in Analyst Recommendations: Vaxart, Inc.

a05996dd532dceffcda7.s_olhFhyMCvtti09AjbzkHP_b-ASJICd1oP1bFJbwLw.4YJKxg1BQGWegntOTmK0-TWNAtRcd-Sv7tuBMzho94jhvmDldSJ4G4jxWg~6c2f26e93012d171ea81fca1753f53c1
25-03-27 B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating MT
24-08-15 Oppenheimer Initiates Vaxart at Outperform With $4 Price Target MT
24-06-14 B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating MT
24-01-31 B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50 MT
23-08-07 Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating MT
22-12-19 B. Riley Lowers Vaxart's PT to $1.50 From $6, Reflecting More Conservative Estimate of Ramp-up of Norovirus; Keeps Neutral Rating MT
22-09-02 Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating MT
22-05-19 B. Riley Trims Vaxart's Price Target to $6 from $7 to Reflect Modest Increased Long Term Cost of Capital Amid Current Macro Conditions; Keeps Neutral Rating MT
22-03-07 B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating MT
21-12-29 Jefferies Analyst Starts Vaxart at Buy, Adjusts Price Target to $12 From $13 MT
21-11-02 Cantor Fitzgerald Starts Vaxart at Overweight With $15 Price Target MT
21-06-30 VAXART : B. Riley Downgrades Vaxart to Neutral from Buy, Lowers PT to $9 from $13 on 'Underwhelming' Immunogenicity Dataset, Challenging Near-term Catalyst Setup MT
21-06-24 VAXART : Jefferies Initiates Coverage on Vaxart With Buy Rating, $13 Price Target MT
21-06-11 VAXART : Piper Sandler Starts Vaxart at Overweight With $18 Price Target MT
21-03-04 VAXART : B. Riley Lowers Vaxart's Price Target to $13 from $16, Keeps Buy Rating MT
20-11-18 VAXART : B. Riley Adjusts Vaxart PT to $16 From $22, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+505.51%
+12.99%
+17.61%
+52.8%
+2.59%
+28.68%
+20.39%
+5.12%
-13.44%
-2.09%
Average +63.01%
Weighted average by Cap. +16.65%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5505USD
Average target price
3.333USD
Spread / Average Target
+505.51%
High Price Target
4.000USD
Spread / Highest target
+626.61%
Low Price Target
2.000USD
Spread / Lowest Target
+263.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

B. Riley
Cantor Fitzgerald
Jefferies & Co.
Piper Sandler
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5505USD
Average target price
3.333USD
Spread / Average Target
+505.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock
  4. Consensus Vaxart, Inc.